• Read more about Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Predicted Novel Biomarkers for Hyper-CVAD (CVAD) Treatment Response and Combination of Rituximab and Cladribine (RC) in CVAD Resistant Cases of Mantle Cell Lymphoma (MCL)

Background: Mantle Cell Lymphoma (MCL) accounts for 3-10% of all non-Hodgkin lymphomas with a median overall survival of 3-4 years. Hyper-CVAD (CVAD) with or without Rituximab constitutes first line therapy for treatment of MCL, yet the use of this combination is associated with high toxicity and only modest efficacy. On the other hand, impressive clinical efficacy has been reported in relapsed MCL patients treated with rituximab and cladribine (RC).